288 related articles for article (PubMed ID: 28337964)
1. Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model.
Tao H; Qian P; Wang F; Yu H; Guo Y
Oncol Res; 2017 Nov; 25(9):1579-1587. PubMed ID: 28337964
[TBL] [Abstract][Full Text] [Related]
2. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
4. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
7. Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8
Chen X; Wang L; Li P; Song M; Qin G; Gao Q; Zhang Z; Yue D; Wang D; Nan S; Qi Y; Li F; Yang L; Huang L; Zhang M; Zhang B; Gao Y; Zhang Y
Int J Cancer; 2018 Nov; 143(10):2561-2574. PubMed ID: 29981155
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
9. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
10. Tumoral and paratumoral NK cells and CD8
Strizova Z; Vachtenheim J; Snajdauf M; Lischke R; Bartunkova J; Smrz D
Sci Rep; 2020 Aug; 10(1):13936. PubMed ID: 32811852
[TBL] [Abstract][Full Text] [Related]
11. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Hatogai K; Kitano S; Fujii S; Kojima T; Daiko H; Nomura S; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
Oncotarget; 2016 Jul; 7(30):47252-47264. PubMed ID: 27322149
[TBL] [Abstract][Full Text] [Related]
13. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma.
Suzuki S; Yokobori T; Tanaka N; Sakai M; Sano A; Inose T; Sohda M; Nakajima M; Miyazaki T; Kato H; Kuwano H
Oncol Rep; 2012 Aug; 28(2):465-72. PubMed ID: 22641236
[TBL] [Abstract][Full Text] [Related]
14. Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis.
Wang B; Qin L; Ren M; Sun H
Cell Physiol Biochem; 2018; 49(1):260-270. PubMed ID: 30138920
[TBL] [Abstract][Full Text] [Related]
15. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
16. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
18. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
19. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
20. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
